Wall Street analyst estimates for Sagimet Biosciences Inc. (SGMT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.25 | ||
| 2026-08-11 | $-0.26 | $-0.25 | -3.6% |
| 2026-05-12 | $-0.33 | $-0.39 | +15.4% |
| 2026-03-11 | $-0.29 | $-0.43 | +32.6% |
| 2025-11-13 | $-0.40 | $-0.41 | +2.4% |
| 2025-08-13 | $-0.32 | $-0.52 | +38.5% |
| 2025-05-08 | $-0.56 | $-0.79 | +29.1% |
| 2025-03-12 | $-0.50 | $-0.65 | +23.1% |
Valuation Ratios
| Price / Book | 2.17 |
| EV / EBITDA | -3.87 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $2.0M | 0 | 0 |
| Cost of Revenue | $88000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$88000 | 0 | 0 | 0 | $2.0M | 0 | 0 |
| Research & Development | $8.4M | $8.2M | $19.3M | $24.9M | $19.8M | $38.4M | $39.1M |
| Selling, General & Admin | $5.7M | $3.2M | $4.4M | $6.1M | $13.0M | $16.0M | $17.8M |
| Operating Expenses | $14.1M | $11.4M | $23.7M | $31.1M | $32.7M | $54.5M | $56.9M |
| Operating Income | -$14.2M | -$11.4M | -$23.7M | -$31.1M | -$30.7M | -$54.5M | -$56.9M |
| EBITDA | -$14.1M | -$11.4M | -$24.4M | -$30.4M | -$27.9M | -$45.6M | -$51.0M |
| Interest Expense | $64000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$14.3M | -$11.4M | -$24.4M | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.3M | -$11.4M | -$24.4M | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| EPS | $-0.64 | $-0.51 | $-1.10 | $-1.38 | $-1.53 | $-1.45 | $-1.58 |
| EPS (Diluted) | $-0.64 | $-0.51 | $-1.10 | $-1.38 | $-1.53 | $-1.45 | $-1.58 |
| Shares Outstanding (Diluted) | $22.2M | $22.2M | $22.2M | $22.2M | $18.2M | $31.4M | $32.3M |
Price
| Price | $10.46 |
| Market Cap | $341M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of SGMT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks